VAXCYTE INC (PCVX:NASDAQ)
$56.04 -0.7 (-1.2337%)
Analysed VAXCYTE INC (PCVX:NASDAQ) News Sources
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
24-05-2026
fool.com
Vaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical Trials
29-05-2026
yahoo.com
Why Vaxcyte (PCVX) Is Up 8.7% After Completing Key VAX-31 Phase 3 Trial Enrollments
01-06-2026
yahoo.com
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
02-06-2026
yahoo.com
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
03-06-2026
fool.com
Pneumonia Market Set to Witness Robust Growth During the Forecast Period (2026-2036), Driven by Advancing Therapeutics and Rising Disease Burden | DelveInsight
08-06-2026
yahoo.com
Vaxcyte (PCVX) Conducts Initial Dosage for VAX-A1 Phase 1 Study
17-06-2026
yahoo.com
Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine
22-06-2026
yahoo.com
Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now
03-07-2026
yahoo.com
Vaxcyte to Participate in Upcoming Investor Conferences
08-07-2026
yahoo.com
What is the current price of VAXCYTE INC (PCVX:NASDAQ)?
The current price of VAXCYTE INC (PCVX:NASDAQ) is $56.04.
VAXCYTE INC (PCVX:NASDAQ) absolute price change since previous trading day?
The absolute price change of VAXCYTE INC (PCVX:NASDAQ) since the previous trading day is $-0.7.
VAXCYTE INC (PCVX:NASDAQ) percentage price change since previous trading day?
The percentage price change of VAXCYTE INC (PCVX:NASDAQ) since the previous trading day is -1.2337%.
What is the most recent average sentiment score for VAXCYTE INC (PCVX:NASDAQ)?
The most recent average sentiment score for VAXCYTE INC (PCVX:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for VAXCYTE INC (PCVX:NASDAQ)?
The most recent sentiment for VAXCYTE INC (PCVX:NASDAQ) is .
SEC-8K** Filing Available For VAXCYTE INC (PCVX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.